BASEL, Switzerland,
April 17, 2017 /PRNewswire/
-- Axovant Sciences Ltd. (NYSE: AXON) ("Axovant"), a leading
clinical-stage biopharmaceutical company focused on the treatment
of dementia, today announced the closing of its underwritten public
offering of 7,753,505 of its common shares at a price to the public
of $18.54 per common share, including
1,011,326 common shares sold pursuant to the underwriters' exercise
in full of their option to purchase additional common shares. Gross
proceeds to Axovant from the offering were approximately
$143.7 million, before deducting
underwriting discounts and commissions and estimated offering
expenses.
J.P. Morgan, Morgan Stanley and Jefferies acted as joint
book-running managers for the offering. JMP Securities,
Baird and H.C. Wainwright & Co.
acted as co-managers.
A shelf registration statement relating to the offered common
shares was filed with the Securities and Exchange Commission (SEC),
and was declared effective on January 13,
2017. A final prospectus supplement and accompanying
prospectus relating to the offering have been filed with the SEC
and are available on the SEC's website, located at
www.sec.gov. Copies of the final prospectus supplement and
accompanying prospectus related to the offering may be obtained
from J.P. Morgan Securities LLC, c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, toll-free: (866) 803-9204,
email: prospectus-eq_fi@jpmchase.com; Morgan Stanley & Co. LLC,
Attention: Prospectus Department, 180 Varick Street, 2nd Floor,
New York, New York 10014; or
Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, 2nd Floor, New York,
NY 10022, telephone: (212) 336-7460, e-mail:
Prospectus_Department@Jefferies.com.
This announcement is neither an offer to sell nor a solicitation
of an offer to buy any of these securities, and shall not
constitute an offer, solicitation, or sale in any jurisdiction in
which such offer, solicitation, or sale is unlawful.
About Axovant
Axovant Sciences is a leading
clinical-stage neurology company focused on the treatment of
dementia and related neurological disorders. Axovant is developing
a pipeline of product candidates to comprehensively address the
cognitive, functional, and behavioral aspects of dementia. Our
vision is to become the leading company focused on the treatment of
dementia by broadly addressing multiple forms of this condition
through developing innovative new medicines for patients.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/axovant-sciences-ltd-announces-closing-of-public-offering-and-exercise-in-full-of-the-underwriters-option-to-purchase-additional-common-shares-300440379.html
SOURCE Axovant Sciences Ltd.